The management of advanced non-small cell lung cancer (NSCLC) has evolved with the advent of targeted therapies such as erlotinib, which inhibit epidermal growth factor receptor (EGFR) signaling. However, identifying patients who will benefit from erlotinib remains challenging, particularly in those without known EGFR-activating mutations. This study explores the theranostic potential of early [18F]FDG-PET/CT imaging—performed within two weeks of initiating erlotinib therapy—in predicting treatment response, progression-free survival (PFS), and overall survival (OS) in NSCLC patients.
Twelve patients with unresectable stage IIIA to IV NSCLC underwent three [18F]FDG-PET/CT scans: baseline (PET1), early post-treatment (PET2, 9–63 days after starting therapy), and late post-treatment (PET3, at 60–66 days). Metabolic response was assessed by changes in maximum standardized uptake value (SUVmax) between PET1 and PET2. A ≥21.6% reduction in SUVmax on PET2 was found to be a robust predictor of metabolic non-progressive disease (mNP), with an area under the ROC curve (AUC) of 0.86 (P = 0.04). This threshold correctly classified 11 out of 12 patients, including seven true progressive cases, four true non-progressive cases, and one false positive.
Patients classified as mNP based on early PET demonstrated significantly higher rates of non-progressive disease at eight weeks (P = 0.01, Fisher’s exact test). Moreover, they experienced markedly prolonged PFS (median 292 days vs. 64 days; HR = 0.27; P < 0.01) and OS (median 1031 days vs. 337 days; HR = 0.34; P = 0.03). Late PET imaging confirmed these findings, with all 10 evaluable patients showing concordant results.Bedaquinoline impurity 13 MedChemExpress Notably, the appearance of new lesions on PET3 was observed in patients with poor outcomes, reinforcing the importance of detecting both metabolic suppression and new disease activity.4-tert-Butyltoluene medchemexpress
Despite no significant change in mean SUV values across the three time points, individual patient responses were clearly distinguishable, highlighting the sensitivity of early metabolic imaging to subtle therapeutic effects. The absence of tumor shrinkage on conventional CT did not preclude response, underscoring the limitations of RECIST criteria in evaluating cytostatic agents like erlotinib.PMID:34917923
These results support the use of early [18F]FDG-PET/CT as a theranostic tool that enables rapid assessment of treatment efficacy. By identifying non-responders early, clinicians can discontinue ineffective therapy, avoid unnecessary toxicity, and promptly initiate alternative treatments. This approach may enhance patient outcomes, improve quality of life, and accelerate enrollment in clinical trials. Future prospective, randomized studies are needed to validate this strategy and evaluate its impact on healthcare costs and drug development timelines.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com